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PrevalenceofAlzheimer’sdisease(AD)willreach epidemicproportionsintheUnitedStatesandworldwideinthecomingdecades,
and with substantially higher rates in African Americans (AAs) than in Whites. Older age, family history, low levels of education,
and ε4 allele of the apolipoprotein E (APOE) gene are recognized risk factors for the neurodegeneration in AD and related
disorders. In AAs, the contributions of APOE gene to AD risk continue to engender a considerable debate. In addition to the
established role of cardiovascular disease (CVD) risk in vascular dementia, it is now believed that CVD risk and its endophenotype
may directly comediate AD phenotype. Given the pleiotropic eﬀects of APOE on CVD and AD risks, the higher rates of CVD
risks in AAs than in Whites, it is likely that CVD risks contribute to the disproportionately higher rates of AD in AAs. Though
the advantageous eﬀects of aerobic exercise on cognition is increasingly recognized, this evidence is hardly deﬁnitive, and data on
AAs is lacking. In this paper, we will discuss the roles of CVD risk factors in the development of AD and related dementias, the
susceptibility of these risk factors to physiologic adaptation, and ﬁtness-related improvements in cognitive function. Its relevance
to AD prevention in AAs is emphasized.
1.Introduction
Although anticholinesterase therapies have greatly improved
symptomatic treatment of AD, they have not been demon-
strated to signiﬁcantly slow disease progression. Excess mor-
bidity and mortality from AD continue to generate enor-
mouseconomicburdenonfamiliesandontheUnitedStates.
Preservation of intellectual dexterity among those showing
earliest symptoms of AD may ameliorate the physical,
emotional,andeconomicburdenassociatedwiththedisease,
and that is an important public health goal.
A promising evidence-based and relatively side-eﬀect
free lifestyle approach is emerging as an alternative or ad-
junct to anticholinesterase therapy. Speciﬁcally, aerobic ex-
ercise training has been demonstrated to improve cognitive
function (Figure 1). Though, the eﬀect sizes for these studies
were surprisingly large, and the results fairly consistent,
however, the sample sizes were small and included mostly2 International Journal of Alzheimer’s Disease
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Whites. Importantly, the mechanism by which an advanta-
geous eﬀect occurs is yet to be systematically examined. Re-
markably, aerobic ﬁtness can improve many of the putative
AD risk factors such as high-density lipoprotein cholesterol
(HDL-C), inﬂammation, and arteriolosclerosis. However,
improvements in these risk factors have not been optimally
explored as potential mechanisms by which aerobic training
improvescognitivefunctioninhumansandAAinparticular.
Given that AAs (i) have higher incidence and prevalence of
AD than Whites, (ii) have paucity of cross-sectional and lack
prospective data on the beneﬁcial eﬀect of exercise on cog-
nitive function and (iii) are more sedentary relative to
Whites, in whom data show the beneﬁcial eﬀect of exercise,
andthereforehavemoreroomforexercise-inducedimprove-
ments in risk, it is relevant that the beneﬁcial eﬀects of aero-
bic ﬁtness on neurocognitive processes is prospectively ex-
amined in this population.
2. Magnitudeof Alzheimer’s DiseaseBurden
Clinically, AD is a constellation of gradual decline in mem-
ory, other cognitive functions, behaviors, and activities of
daily living leading to total dependency [1]. Pathologically,
AD is a heterogeneous neurodegenerative disorder cha-
racterized by amyloid-beta plaques(Aβ),neuroﬁbrillary tan-
gles, inﬂammation, and neuronal loss. AD is the most com-
mon type of dementia constituting ∼2/3rd of all late-life
dementias and is estimated to aﬀect 8 percent of persons
age 65 years or older [2]. The prevalence of AD increased
about 15-fold from 3 percent among individuals between the
ages of 65, and 74 years to 47 percent for persons age 85
and older [3]. Also, the incidence of AD increased from 0.5
percent per year at age 65, to ∼8p e r c e n tp e ry e a ro v e ra g e8 5
[4, 5]. Without AD, hypertension, and other chronic age-re-
lated medical conditions, many older persons would remain
relatively functional until late in life, contributing to society.
That would reduce the nation’s dependency ratio [6]. Based
on 1999 estimates, the annual health care cost for AD was ∼
$100 billion [7]. Excluding ∼$202 billion in uncompensated
careby ∼15millionfamiliesandcaregivers,totalpaymentsin
2011 for health care, long-term care, and hospice services for
people aged ≥6 5y e a r sw i t hA Da n do t h e rd e m e n t i a sw e r e
estimated to be $183 billion [8]. Given this staggering cost
and the projected increase in elderly population by the year
2050, identifying eﬀective mechanisms to ward oﬀ structural
and functional declines of AD is an important public health
goal.
3. AD inAfricanAmericans
The incidence and prevalence of AD is higher in AAs than
Blacks from Sub-Sahara African and compared to persons
of European descent. In spite of this statistics, the disease is
u n d e r s t u d i e di nA A s[ 9]. In the Multi-Institutional Research
on Alzheimer’s Disease Genetic Epidemiology (MIRAGE)
study led by Farrer et al., the adjusted cumulative risk ofInternational Journal of Alzheimer’s Disease 3
Table 1: Number of deaths, population, and rate of death per 100,000 with underlying or contributing cause coded as dementia by division
and race in persons aged 65 and over: United States 1999–2004.
Division Race Death 65y+ Population 65y+ Crude rate 65y+ Age adjusted rate 65y+
New England Black or African American 1,683 340,854 494 574
White 77,719 10,875,302 715 633
Middle Atlantic Black or African American 10,145 3,119,034 325 362
White 155,700 28,965,773 538 492
East North Central Black or African American 17,106 2,836,888 603 671
White 219,113 31,040,245 706 664
West North Central Black or African American 3,476 493,880 704 757
White 115,938 14,864,882 780 687
South Atlantic Black or African American 37,538 5,553,447 676 731
White 240,812 36,129,123 667 676
East South Central Black or African American 11,422 1,798,196 635 625
White 75,592 11,093,302 681 721
West South Central Black or African American 12,364 2,158,225 573 597
White 118,490 18,293,681 648 676
Mountain Black or African American 1,242 232,688 534 688
White 78,387 12,005,553 653 687
Paciﬁc Black or African American 8,352 1,283,968 650 725
White 181,815 25,078,447 725 683
US total Black or African American 103,328 17,799,544 581 628
White 1,263,566 188,249,878 671 647
dementia in the ﬁrst degree relatives of probands with AD
in AAs was approximately twice that of a similar White sam-
ple. According to reports from the Indianapolis-Ibadan De-
mentia Project, the rates of AD and dementia in Yoruba (an
ancestral population in Nigeria) are less than half the rates
in AAs [10], suggesting possible contributions from the en-
vironment.
To better discern the relatively high rates of AD in AAs, a
number of studies have compared the prevalence and inci-
dence of AD and related disorders across populations in
the US. Whereas a faster rate of cognitive decline in Mild
Cognitively Impaired (MCI) AAs than in non-AA was ob-
served in one study that used a community-based sample
[11], others found no evidence of racial disparities in cog-
nitive trajectories of MCI [12, 13]. However, in AAs compar-
ed to Whites, a signiﬁcantly slower rate of cognitive decline
was reported once AD begins [13, 14]. For example, using
age and education adjusted growth curve approach to esti-
mate individual paths of change in global cognition, Barnes
reported that older AAs had a lower level of global cognition
at baseline and declined at ∼25% slower rate compared to
Whites [14]. In another study that examined the severity of
AD at the time of presentation to the medical establishment
among diﬀerent ethnic groups in the US, minority persons
(including AAs) compared to Whites tended to exhibit a
more severe proﬁle of AD at the time of presentation [15].
Despite such relatively slower rate of AD progression, AA
MCI and incident AD patents experienced greater decline
in body mass index (BMI) compared to normal controls
[16]. While the biologic explanation for the lower rates
of cognitive decline in AAs needs further elucidation, an
enriched social network has been proposed as a possible ex-
planation [17]. Collectively; a higher incidence and greater
rate of cognitive decline in MCI and AD-aﬄicted AAs, de-
layed diagnosis, lower rate of cognitive decline once AD oc-
curs together with an accelerated weight loss suggest that
the overall prevalence of AD in this population will reach
epidemic proportions in the coming decades. Decreased
overall wellness and increased health disparity are notable
consequences. Given the eﬀects of socioeconomic variables
and access to health care on these important health indi-
cators, such consequences may become blurred by regional
variations. In support of this view, we recently reported that
racial diﬀerences in AD or dementia mortality varied by
regions in the United States (Table 1)[ 12, 18]. A fundamen-
tally important implication of these observations is that
other factors at the environment or genetic level may con-
tributetohigherincidenceandprevalenceofADinAAsthan
in Whites. Increased CVD risks and low levels of physical ac-
tivity may explain some of these diﬀerences.
At the genetic level, APOE gene is the most consistent
nondeterministicgeneticriskfactorforAD.Itscontributions
to AD risk are graded across alleles (ε2, ε3a n dε4), with
ε4 conferring the highest risk [19, 20]. While many believed
that the contributions of the ε4 allele to AD risk are similar
across populations [21, 22], others have reported a lower
associated AD risk in AAs than in Whites [23, 24]. Using
pooledsamplesfromtheMIRAGE,Alzheimer’sDiseaseNeu-
roimaging Initiatives (ADNI), Canadian Study on Genetics
of Alzheimer’s Disease Association (GenADA), and National
Institute on Aging-Late-Onset Alzheimer’s Disease Family
Study (NIA-LOAD) data, we reported that the presence of ε44 International Journal of Alzheimer’s Disease
allele signiﬁcantly and exponentially associated with AD in
AAs in a dose-dependent manner. However, the odds ratio
estimates in ε4 carriers showed lower rates of AD in AAs
compared to Whites (63.1 percent versus 67 percent). Con-
versely, we also observed a higher occurrence of ε4i nA A
controls than White controls (40.1 percent versus 29.1 per-
cent), respectively [25]. These suggest that the ε4a l l e l e
of the APOE gene may interact with other risk factors to
cause a diﬀerential AD risk in AAs compared to Whites. In-
terestingly, AAs also have increased CVD risks such as hy-
pertension, diabetes, and hypercholesterolemia. Evidently,
key interactions of APOE gene with CVD risk such as lipids,
inﬂammation, glucose homeostasis, and lifestyle factors in
these populations must be considered [26]. Such factors may
lend themselves to interventions capable of attenuating AD
risk in AAs and other populations at risk.
Attheenvironmentlevel,growingevidenceindicatesthat
aerobic ﬁtness can reduce AD risk in predominantly White
samples. However, these advantageous eﬀects of exercise are
yet to be validated in a relatively more sedentary AA sample
[27]. Given the higher rates of AD in AAs than in Whites and
thelackofsubstantivediﬀerencesinADneuropathology[28,
29],itislikelythatAAmildADpatientswillalsobeneﬁtfrom
the advantageous eﬀects of aerobic ﬁtness. In addition to the
public health imperative, such intervention may ameliorate
the physical, emotion, and economic burden associated with
AD. All of these eﬀects will beneﬁt society at large.
4. Rationale for Dementia Prevention
Whereas, it is established that the preservation of neurocog-
nitive function among those showing earliest signs and sy-
mptoms of AD can attenuate the burden associated with
the disease; unfortunately, this beneﬁt and the national goals
of Healthy People 2010 cannot be realized without an eﬃ-
cient AD prevention strategy. Moreover, while medical treat-
ment after disease onset may reduce disease progression and
mortality,eventually,increasesindiseaseprevalencewillsub-
stantially escalate total disease burden and healthcare cost
for the population. Though the current approach to symp-
tomatic treatment of AD may not be cost-eﬀective in popu-
lations with excessive rates of disease such as AAs, a low-cost
low-risk intervention strategy with dual applicability for pri-
mary and secondary prevention is likely to be advantageous.
The goal of this paper, therefore, is to enhance scientiﬁc
discuss on the role of CVD risk in the development of
AD and related dementias and to add clarity to the clinical
utility of ﬁtness adaptation in preventing AD in those at risk.
However, signiﬁcant uncertainty in disease progression from
prodromal to symptomatic AD raises an important ques-
tion of whether intervention should be directed at the fully
characterized MCI or AD clinical phenotypes. Because of
thepresentimpracticalityofreversingneuronaldeathunder-
lying the AD phenotype, interventions are likely to yield the
most beneﬁt if initiated at the earliest possible stage as in
pre-MCI. Indicators of such timely intervention may include
notable endophenotype such as decreasing cerebrospinal
ﬂ u i d( C S F )l e v e l so fA β that precede the emergence of the
MCI clinical phenotype. If conﬁrmed in randomized clinical
trials, aerobic ﬁtness can become an eﬀective public health
tool to combat AD risk. Such a low-cost low-risk eﬀective
strategyislikelytoreducetheburdenofdiseaseandoptimize
the well-being of older adults at increased AD risk.
5.CardiovascularDiseaseRiskin
AD Development
Stroke and Alzheimer’s type dementia increase at compara-
ble rates with advancing age. Atherosclerosis, hypertension,
diabetes mellitus, and lipids are major CVD risk factors
shown to be associated with AD [30]. Recently, Arvanitakis
andcolleaguesreportedanassociationofdiabeteswithsema-
ntic memory impairment in both Blacks and Whites [30].
The Rotterdam population-based prospective study that
examined approximately 8000 subjects over age 55 for the
frequency of lifetime risk of dementia and its subtypes, in-
cluding AD, showed an increase in the prevalence of athero-
sclerosis in both vascular dementia and AD [31]. Also,
compilation of autopsy reports on AD brains indicate, that
approximately 60–90 percent of the cases exhibited vari-
able cerebrovascular pathology synonymous with CVD [28–
32]. In AD cases ascertained by the presence of amyloid angi-
opathy, endothelial degeneration, and periventricular white
matter lesions at autopsy, Van Nostand showed that ∼1/3rd
had evidence of cerebral infarction [33]. However, in a study
to examine the relationship of important AD intermediate
phenotype such as diﬀerences in brain volume, hippocampal
volume and cerebrovascular risk factors, and APOE4 among
MCI subtypes, He and colleagues found CVD risk factors to
bemorecloselyrelatedtononamnesticMCIandvascularde-
mentia; though emphasized that the biological diﬀerences
between amnestic (AD group) and nonamnestic (presumed
vascularetiology)wereverysubtle[34].Giventheseobserva-
tions, it is possible that CVD risks plays a greater role in cog-
nitive decline in older AAs compared to Whites. In support
of this view, Brickman et al. demonstrated more severe white
matter hyperintensity (WMH) burden in AAs and Hispanics
compared to Whites [35]. In particular, vascular disease was
associated with relatively smaller brain volume and higher
WMHburdeninAAs.Othershavealsodemonstratedgreater
degree of psychomotor impairment, a surrogate for higher
cerebrovascular burden in AAs than in Caucasians [36].
Collectively, these reports indicate that CVD risk factors may
also inﬂuence cognitive loss, particularly in AAs who suﬀer a
greater burden of CVD risk and related brain pathology.
Regardless of whether increased CVD risk burden cul-
minates into vascular dementia, enables or directly promote
AD pathology [37–42], with or without interactions with
age-associated decline in health status [43], interventions
directed at reducing CVD risk factors may attenuate declin-
ing cognitive dexterity especially in older AAs. Despite the
evidence showing a higher degree of CVD risks and cere-
brovascular pathology in AAs, data is lacking on whether
aerobic ﬁtness-induced reduction in CVD risk can concomi-
tantly reduce AD risk in this population. Given that AAs
suﬀer a high CVD-related morbidity, they are likely to bene-
ﬁt from CVD risk reduction measures. Collection of pro-
spective data on putative CVD mediators of AD and theirInternational Journal of Alzheimer’s Disease 5
susceptibility to ﬁtness adaptation will elucidate its clinical
utility in ameliorating AD risks in AAs and other popula-
tions.
6.Mechanismsby WhichCardiovascular
DiseaseRisk CanInﬂuence AD
6.1. Association of Total Cholesterol with AD Risk. Disorder
of brain cholesterol metabolism has been associated with
all principal pathological features of AD such as synaptic
transmission [44], amyloid [45], and tau pathology [44].
Lipids and lipid peroxidation products have important roles
in the homeostasis of the central nervous system [46]. In ani-
mal and in vitro studies, Golde and colleagues showed that
overexpression of cholesterol resulted in the formation of
amyloidβandcontributedtothedegradationofneuronsand
subsequent cognitive impairment [47]. Also, lipid transport
genes and vascular changes associated with peripheral dys-
lipidemia have been associated with an increased risk of AD.
This indicates that lipids may be involved in the pathogenesis
of neurodegeneration and related dementias. Alternatively,
lack of cholesterol supply to the neurons via lipoprotein
transport may cause failure of neurotransmission and synap-
tic plasticity [48]. However, because almost all brain choles-
terol is a product of local synthesis, with brain blood barrier
eﬃciently protecting it from exchange with lipoprotein
cholesterolinthesystemiccirculation[49],serumcholesterol
may not accurately reﬂect the related AD risk. Moreover, the
bimodal relationship of serum cholesterol with health may
contributetotheinconsistenciesofreportsontheassociation
of cholesterol with cognitive health, especially when the
protective inﬂuence of HDL-C is not considered.
6.2. Association of High-Density Lipoprotein Cholesterol with
AD and CVD Risk. HDL-C is an important risk factor for
CVD [50, 51]. As with CVD risk, the contribution of HDL-C
to AD risk is increasingly recognized. HDL-C functions to
both keep its lipid components soluble and also provide an
eﬃcient mechanism for their transportation through plasma
andtoorfromthetissues.LowHDL-C,togetherwithsubop-
timal transport system in humans, results in gradual deposi-
tionoflipid(especiallycholesterol)intissuescausingarterio-
lar narrowing and chronic cerebral oxygen deprivation [52].
6.3. HDL-C Is the Predominant Lipoprotein in Human Brain
Circulation, and Its Low Levels Have Been Associated with
Impaired Memory [53–55]. For example, Wolf and colle-
agues recently showed that low levels of HDL-C and not LDL
or total cholesterol levels were associated with hippocampus
atrophy in aged humans [56]. Unlike total cholesterol,
HDL-C brain level correlates with its plasma concentration.
This evidence suggests that low levels of HDL-C may play
an important role in AD risk. Beyond the direct eﬀect of
low HDL-C on arteriolosclerosis, high HDL-C may con-
versely inﬂuence AD risk in three other important ways: (i)
mediation of reduced inﬂammatory cytokines which is cen-
tral to arteriolar narrowing; (ii) through its interaction with
Aβ to form soluble HDL-C-Aβ complex (Figure 2); (iii) its
antioxidant property.
6.4. Evidence of Anti-Inﬂammatory Eﬀects of HDL-C. In sup-
port of HDL-C anti-inﬂammatory eﬀects, Cockerill and col-
leagues showed that, in physiological concentration, isolated
plasma HDL-C inhibited tumor necrosis factor-α (TNF-
α) or interlekin-1 (IL-1) and reduced leukocyte adhesion
molecules in a concentration-dependent manner (Figure 2)
[57]. Others have reported increased markers of inﬂamma-
tion with low HDL-C levels [58]. Therefore, as the predo-
minant lipoprotein in the brain circulation, the anti-inﬂam-
matory eﬀects of high HDL-C may play an active role in
reducing vascular inﬂammation and arteriolosclerosis of the
cerebral circulations. This may enhance brain oxygenation
and preserve neurocognitive dexterity.
6.5. Evidence of Antiamyloid Deposition Eﬀects of HDL-C.
The interaction of HDL-C with Aβ is consistent with its neu-
roprotective eﬀects. For example, HDL-C attenuates the
aggregation and polymerization of Aβ protein (Figure 2)
[59]. Using thioﬂavin T ﬂuorescence, Olesen and Dagø
showed that HDL-C reduced amyloid formation in vitro.
Additionally, the association of HDL-C with Aβ was also
recently demonstrated by Koudinov et al. who isolated HDL-
Aβ complexes from CSF [60]. More support for the direct
eﬀects of HDL-C on Aβ was evidenced by studies showing
thatAβmediatedthecellularuptakeoflipoproteins[61],and
that HDL-C induced increases in the cellular degradation of
Aβ in cultured microglia [62]. Its neuroprotective property
against Aβ was also demonstrated by Farhangrazi et al., who
showed that the neurotoxic eﬀect of Aβ in cortical cell cul-
tures became attenuated in the presence of high levels of
HDL-C [63]. It is therefore likely that HDL-C exerts a sig-
niﬁcant antiamyloid eﬀect that may be susceptible to lifestyle
alteration.
6.6. Evidence of Antioxidant Eﬀect of HDL-C. Growing evi-
dence suggests that oxidative damage is implicated in neu-
ronal degeneration that occurs in AD brains [64, 65]H i g h -
plasma HDL-C particles can also exert antioxidant activity
and have the capacity to protect low-density lipoprotein
(LDL) against oxidative stress [66]. Though the exact mech-
anism by which HDL-C exerts antioxidant eﬀects needs furt-
her clariﬁcation, its role as a transporter of enzymes exerting
antioxidativeactivitysuchasparaoxonase(PON)[67],plate-
let-activating factor acetylhydrolase (PAF-AH) [68] and leci-
thin-cholesterol acyltransferase (LCAT) [69]m u s tb en o t e d .
Moreover, intrinsic antioxidative property of HDL-C sub-
fraction is deﬁcient in the presenceoflow HDL-Cphenotype
and ampliﬁed by low number of circulating HDL-C parti-
cles. Indeed, this dysfunctionality is closely related to ele-
vated oxidative stress evidenced by breakdown products of
arachidonic acid such as plasma isoprostane.
In summary, given the eﬀects of high HDL-C levels on
the biochemical properties of Aβ and its antioxidant pro-
perty, it is likely that HDL-C plays a direct role in brain
amyloid deposition and AD risk. Because high HDL-C can
reduce inﬂammation, enhance lipid metabolism, and there-
fore reduce arteriolosclerosis and enhance brain perfusion, it
islikelytobeimportantforoptimalneurocognitivefunction.
Fortunately, HDL-C is susceptible to the eﬀects of aerobic6 International Journal of Alzheimer’s Disease
APP
degradation
Exercise
(independent of or interactively with APOE)
(IV) Improves
lipids
metabolism
Aβ
(pathologic
state)
HDL-Aβ
complex
Amyloid
deposition
Amyloid
deposition
(V) Reduces
inﬂammation
Decreases
inﬂammation
Decreases leukocyte
adhesion molecule
Inhibits TNF-α
HDL-C
Hypertension
TC, LDL-C,
TGL
Glucose
phosphory-
lation
Hypergly-
cemia
(I) Improves
brain
perfusion
Micro-
(Ia) Reduces endothelia
dysfunction and
arteriolosclerosis
Endothelia
dysfunction
(ENOS)
HIF-1
Blunted
response
Hypogl-
ycemia
(Ib) Reduces susceptibility
to hypoxia
Susceptib-
ility to
hypoxia
Chronic
deprivation
Promotes Aβ
formation
Aβ
(
I
I
)
 
I
m
p
r
o
v
e
s
 
g
l
u
c
o
s
e
h
o
m
e
o
s
t
a
s
i
s
(
V
I
)
 
I
n
c
r
e
a
s
e
s
H
D
L
-
C
With
exercise
W
i
t
h
o
u
t
e
x
e
r
c
i
s
e
aggregation
(
I
I
I
)
 
I
m
p
r
o
v
e
s
 
b
l
o
o
d
p
r
e
s
s
u
r
e
N
o
r
m
a
l
A
l
z
h
e
i
m
e
r
’
s
Arteriolosclerosis
brain O2
angiopathy
Figure 2: Interaction of HDL-C with AD risk factors. Relationships of exercise to prevention of intracerebral amyloid deposition.
exercise training. Our own aerobic ﬁtness data indicated that
a 6-month aerobic exercise-training can improve protective
HDL-ClargeparticlesizeinAAs[70].Whetherthisimprove-
menttranslatesintoimprovementincognitivefunctionisthe
subject of our ongoing investigations.
6.7. Association of Inﬂammation with AD Risk. Though con-
siderable uncertainty exists on the exact role of the inﬂam-
mation in AD, many studies have documented the asso-
ciation of inﬂammatory markers such as CRP and IL1a
with AD. The role of inﬂammation has become even more
evident with recent studies on microglia. Microglia, a dis-
tinct population of brain-resident macrophages, is indicative
of ongoing chronic inﬂammation in AD. In support of
anti-inﬂammatory role of microglia, Minagar and McGeer
demonstrated its activation in regions of the brain showing
AD pathology [71, 72]. Building on earlier observations,
Frank et al. recently examined the association of inﬂamma-
tion with the neuropathology of AD and showed that micro-
glia are present in close association with aggregated types of
Aβ plaques and around neuroﬁbrillary tangles [73]. Frank
et al. also showed that microglia-derived factors including
reactive oxygen species and tumor necrosis factor-α (TNF-
α) are neurotoxic [73]. Neuronal damage by microglia can
also occur when activated microglia and reactive astrocytes
surrounding intracellular deposits of Aβ protein initiate an
inﬂammatory response [74]. Often, this type of response
is characterized by local cytokine-mediated acute phase
response and activation of the complement cascade [74].
However, studies on the eﬀects of anti-inﬂammatory
agents on AD risk are inconclusive. For example, a ret-
rospective study of long-term users of nonsteroidal anti-
inﬂammatory drugs showed a lower incidence of AD in this
population [75]. Conversely, recent clinical trials found no
beneﬁt to the use of nonsteroidal anti-inﬂammatory drugs
(NSAIDs) [76, 77]. Since the actual dose, duration, and
period of protective NSAID use are unknown, these negative
results are hardly deﬁnitive. Further, many of these studies
didnotaccountforgeneticmediatorsofinﬂammatorymark-
ers. Notable among such markers are interleukins andInternational Journal of Alzheimer’s Disease 7
C-reactive protein (CRP). We and others have shown that
aerobic ﬁtness either independently or interactively with its
genetic mediators can reduce CRP level [78, 79]. Whether
training-induced reductions in inﬂammation and CRP levels
translate into improvements in cognitive performance has
not beenstudied. Inour currentlyongoing pilot clinical trial,
we will further delineate the role of inﬂammation in AD,
its association with HDL-C and Aβ protein, and whether
exercise-related changes in inﬂammatory markers are asso-
ciated with neurocognitive measures that are used in this
study. Demonstration of concomitant reduction in inﬂam-
matorymarkers,withimprovementsinneurocognitivefunc-
tion after aerobic exercise training, will be important evi-
dencesupportingtheroleofinﬂammationinAD.Thiswould
beindicativeofthesusceptibilityofADriskfactorstoaerobic
ﬁtness.
7. Associationof HypertensionwithAD Risk
Growing evidence indicates a causal role of hypertension for
cognitive decline of theAlzheimer’s type dementia (Figure 2)
[80, 81]. A few longitudinal studies have also emphasized
a connection between high blood pressure in midlife and
dementia in late life [80, 81]. Recently, Korf and colleagues
reported an association of systolic blood pressure (SBP)
and pulse pressure (PP) with medial temporal lobe atrophy
(MTA), a hallmark of AD, in individuals with late onset
dementia, especially when coexisting with white matter
changes[82].ThesereportsindicatethatCVDriskfactorsin-
cluding hypertension may also inﬂuence AD risk. Our own
data from the NHANES III support these observations.
Though the optimal BP for cognitive performance remains
poorly deﬁned and evidence is emerging on the eﬀects of
CVD-related genes such as ENOS and ACE on AD, the com-
bined eﬀects of hypertension and genetics on neurocognitive
function need clarity. Like many other CVD-related AD risk,
considerable evidence suggests that ﬁtness adaptation can
reduce blood pressure [83–85]. However, whether a con-
comitant improvement in neurocognitive performance oc-
curs with aerobic ﬁtness-related improvements in blood
pressure has not been examined. Even if very small cognitive
beneﬁt accrues from blood pressure reduction, substantial
gains can be realized, given the relatively high prevalence of
hypertension in the United States and in the World.
8.AssociationofHypoxiaandGlucose
HomeostasiswithADRisk
Neurons are highly vulnerable to impairments of oxygen
homeostasisbecauseoftheirsingulardependencyonoxygen.
Though the human brain averages about 2 percent of body
mass, it utilizes 15 percent of cardiac output and 20 percent
of respiratory oxygen uptake. In neural cells in primary cul-
ture and in the hippocampus using in vivo models, both cy-
cloo-2 (COX2) and presenile-1 (PS1) are induced after only
about 5 minutes of hypoxia [86, 87]. Cell cultures and trans-
genic models also suggest an interactive relationship of hy-
poxia with microglia activation, neuroinﬂammation, reduc-
ed neuronal function, and apoptosis [88–90]. These reports
are indicative of the independent and collective roles of CVD
risk factors and, importantly hypoxia in AD risk.
Changes in brain glucose metabolism are associated with
AD [91, 92], and the upregulation of glucose metabolism
has been demonstrated to activate the transcription of hy-
poxia inducible factor (Figure 2) (HIF-1) [93]. HIF-1 is a
heterodimeric transcription factor comprised of two sub-
units, HIF-1α and HIF-1β. In normoxic state, the binding
and transcription of hypoxia-inducible genes do not occur
[94]. HIF-1 mediates the adaptation of cells to hypoxia
and hypoglycemia by upregulating genes involved in glucose
transport and glycolysis [93]. Blunted HIF-1 response to hy-
roxia has been shown to promote Aβ formation and changes
in glucose metabolism. Together, this evidence suggests
that inﬂammation, acting in concert with HIF-1, and glu-
cose metabolism may play an active role in brain cellular
damage and ultimately AD. Fortunately, ﬁtness adaptation
can enhance glucose uptake, increase cerebral perfusion and
possibly favorably regulate the activation of HIF-1. How-
ever, there is no randomized, controlled experiment linking
aerobic ﬁtness to improvements in these intermediate phe-
notypesorneurocognitivefunction.Large-scaleclinicaltrials
are needed to determine whether ﬁtness-related improve-
ments in brain perfusion are eﬀective intervention strategies
to reduce AD risk.
9. ExerciseEffectson CognitiveFunction
9.1. Fitness Training Is Associated with Improved Cognitive
Health in Cross-Sectional and Few Prospective Studies. Cross-
sectional [95, 96], longitudinal [97], and meta-analyses have
demonstrated that improvements in cardiovascular ﬁtness
can improve cognitive function in humans [98, 99]. For ex-
ample,Larsonrecentlyshoweda<3times/weekexercisetobe
related to increased risk of AD compared to >3t i m e s / w e e k
exercise [100]. Others have reported an inverse relationship
of AD with the number of physical activities performed. [96]
In a study of leisure-time physical activity during midlife and
dementia, Rovio et al. reported a reduced risk of AD in those
with higher levels of physical activity [95]. These studies
suggest a signiﬁcant association of physical activity with later
reduction in neurocognitive function and dementia. Not-
withstanding the mostly beneﬁcial eﬀects of exercise ob-
served in the majority of studies, limitations such as self-re-
ported data; failure to distinguish between aerobic and no-
aerobicactivities;failuretoassessexerciseduration,intensity,
and frequency; diﬀerences in the volume of exercise that
is beneﬁcial likely resulted in signiﬁcant variability among
studies.
Toobviatethelimitationinherentincross-sectionalstud-
ies, a few prospective studies have examined the eﬀects of
ﬁtness adaptation on memory. Using meta-analyses of 18
published studies, Colcombe and Kramer found a beneﬁcial
eﬀect of ﬁtness training on an array of neurocognitive pro-
cessinnondementedolderadults[99].Ina ∼7-yearprospec-
tive study of 5925 older women, Yaﬀe et al. demonstrated a
37%reductionintheoddsofcognitivedeclinein3rdquartile
comparedto1stquartileofphysicalactivity[101].Inanother
prospective study, Barnes and colleagues reported better8 International Journal of Alzheimer’s Disease
cardiorespiratory ﬁtness at baseline to be associated with less
cognitive decline at ∼6-year followup [102] .Ar e c e n t2 4 -
week randomized placebo control trial of an unsupervised
physical activity intervention study in MCI-like subjects by
Lautenschlager et al. revealed an improvement of 1.0 points
in ADAS-cog for exercisers, and a deterioration of 1.3 for
controls yielded a total of 2.3 point diﬀerence between the
interventionandcontrolgroupsover6months.Interestingly,
the cognitively beneﬁcial eﬀects of aerobic ﬁtness remained
at 18-month followup [103]. Though these prospective stud-
ies add substantially to the current knowledge and the direc-
tionality of the relationship of aerobic ﬁtness with neu-
rocognitive function, data is lacking on AAs. Importantly, a
more rigorous randomized controlled trial in MCI patients
is needed to establish causality and to clearly delineate the
overall volume of exercise that is beneﬁcial. In spite of the
skepticismontherelativelylargeaerobicﬁtness-relatedeﬀect
size reported in many studies, the multiple levels at which
exercise can inﬂuence AD risk support such observations.
10. Mechanism by Which Exercise Inﬂuences
NeurocognitiveFunction
Mechanism by which aerobic ﬁtness aﬀects neurocognitive
health is yet to be clearly elucidated. Despite the evidence
showing an association between exercise engagement and
improvements in AD biomarkers in cognitively normal older
adults [104] and reports of increased aerobic ﬁtness-related
increases in brain volume in some studies [105–107], the
underlying biological mechanism for these eﬀects needs
further clariﬁcations. Given the available evidence, it appears
that the eﬀects of exercise on neurocognitive function are
mediated through several important pathways. Dyslipide-
mia, especially low HDL-C levels, inﬂammation, deranged
glucose homeostasis, and endothelia dysfunction are pre-
cursors of arteriolosclerosis, decreased cerebral perfusion
and cerebral oxygen deprivation, all of which may increase
AD risk [108, 109]. Aerobic ﬁtness can increase HDL-C,
reduce inﬂammation [78], improve glucose homeostasis
[110], and reduce arteriolosclerosis. Because these beneﬁts
canenhancebrainperfusionandimprovebrainoxygenation,
likely beneﬁts include reduction in AD risk [111]( Figure 1).
Our own analysis of the data from NHANES III supports the
advantageous eﬀects of high levels of HDL-C (Figures 3(a)
and 3(b)). Because exercise can cause reduction in stress
hormone levels known to impair cognitive function [112];
promote neurotrophic changes, nerve cell regeneration, and
neurotransmitter repletion, all of which may enhance cogni-
tive performance [113, 114], these eﬀects are likely involved
in the mechanism by which aerobic ﬁtness aﬀects neurocog-
nitive function. Since the evidence suggests that exercise can
increase solubility of Aβ through increases in HDL-C [62]
and favorably regulate hypoxia inducible factor (Figures 1
and 3), these eﬀects may represent alternative important
mechanism by which exercise exerts its advantageous eﬀect
on neurocognitive function. Training-induced improve-
ments in these putative AD risk factors may precede more
distal eﬀects of ﬁtness adaptation such as increased activity
in the frontal and parietal regions of the brain and increased
graymattervolumeinthefrontalandsuperiortemporallobe
reported by Colcombe and Kramer, respectively [115, 116].
Collectively, these observations indicate that aerobic ﬁtness
may attenuate neurocognitive loss in humans.
11. Limitations of Knowledge on the Effects of
Exerciseon NeurocognitiveFunction
While most of the studies on the eﬀects of aerobic ﬁtness
on cognition are indicative of its beneﬁcial eﬀects, few limi-
tations of these studies must be pointed out. First, most have
not used a standardized exercise protocol, none used rando-
mized controlled design in MCI or mild AD patients. While
the evidence supports an overlap of CVD risk with AD risk
and the responsiveness of CVD risk factor to ﬁtness adapt-
ation, most of the intervention studies thus far have not ex-
plored CVD risk reduction as the mechanism for improve-
ment in cognitive performance. A prospective randomized
controlled trial of aerobic ﬁtness with biomarkers and
neuroimaging will inform the establishment of causality, and
help determine the volume of exercise that is beneﬁcial.
Notably, it will lay the groundwork for the determination of
the role of genetics in aerobic ﬁtness-related eﬀects and the
mechanism by which ﬁtness aﬀects neurocognitive function.
12. Apolipoprotein E Geneas
aM od i ﬁ e ro fA DR i s k
12.1. APOE Is a Risk Factor for AD. T h ee v i d e n c es u g g e s t s
that the APOE gene, especially the 4s u b typ e ,i sam a j o rri s k
factorforsporadicandlate-onsetAlzheimer’sdementia[117,
118]. There are three known common isoforms of APO (E2,
E3,andE4)inhumansencodedbythediﬀerentalleles 2, 3,
and 4. It acts as a receptor of ligands, signifying that intra-
neuronal APOE may be a mechanism by which APOE inﬂu-
ences neuronal repair, regeneration, and survival. Further,
APOE can interact with β-amyloid and tau proteins that are
central to the pathogenesis of Alzheimer’s dementia. Speciﬁ-
cally,thepresenceofAPOElipoproteinincerebralbloodves-
sels laden with amyloid β-protein (A-β)[ 119] is indicative of
the importance of Apoliporotein in the pathogenesis of AD.
12.2. APOE Gene May Inﬂuence AD Risk through Its Eﬀects on
High-Density Lipoprotein Metabolism. Similar to the role of
the 4 allele APOE gene in the pathogenesis of Alzheimer’s
dementia, its association with elevated lipid levels [120]
and atherosclerosis have also been reported [121]. Genetic
variation at the APOE locus can also inﬂuence atherogenesis
through its eﬀects on HDL-C subfractions. APOE aﬀects the
hepatic binding, uptake, and catabolism of several classes of
lipoproteins associated with HDL-C subfractions [122, 123].
The ε2a n dε4 alleles of the APOE gene are associated with
higher and lower HDL-C subfractions, respectively, among
diﬀerent ethnic subgroups and across regional boundaries
[124, 125]. Together, these observations suggest that an in-
dividuals’ genetic makeup, especially at the APOE, locus may
interact with the environment to inﬂuence HDL-C levels.
Because of the importance of apolipoprotein to HDL-C
metabolism and its susceptibility to the inﬂuence of APOEInternational Journal of Alzheimer’s Disease 9
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Figure 3: Adjusted mean short portable MMSE by HDL-C levels and aerobic exercise training.
gene, their combined role in the pathogenesis of AD should
be of signiﬁcant interest.
12.3. African Americans: The Role of APO E in AD Risk. Evi-
dence from protein binding indicates that Aβ interacts with
APOE in an isoform speciﬁc manner, and ﬁbril formation
of Aβ is enhanced by the presence of ε4 allele of the APOE
gene. In its physiologic state, APOE is normally present in
thebraininassociationwithHDL-C-likeparticles.Inviewof
the important role of the ε4 allele and its overrepresentation
in AAs, a proportionately higher ε4-associated AD risk in
AAswouldbeexpected.However,someevidencesuggeststhe
converse.
The interaction of HDL-C with APOE provides a useful
insight into the reduced ε4 allele-associated AD risk, and the
slower rate of AD progression in AAs. Consistently, higher
levelsofHDL-ChavebeenshowninAAsthanelderlyCauca-
sians [126, 127]. In the presence of HDL-C particle, Olesen
and colleagues found no direct eﬀect of APOE on amyloid
formation [59]. This suggest that, though ε4 may increase
the spontaneous amyloid formation of Aβ, HDL-C-bound
Aβ appeartodecreaseamyloidformationasaresultofstrong
amyloid inhibitory eﬀect of HDL-C. Alternatively, ε4a l l e l e
may inﬂuence amyloid formation by aﬀecting the levels of
HDL-C-like particles in the brain. Therefore, because AAs
have relatively higher levels of HDL-C, it is possible that
HDL-C interacts with APOE to reduce the ε4 allele-relat-
ed AD risk and, importantly, lower the rates of disease pro-
gression in this population.
12.4. Combined Eﬀect of APOE Gene and Exercise Training on
HDL-C in AAs. Increased levels of HDL-C and HDL2-C are
the most signiﬁcant changes in lipid and lipoprotein levels
that occur following aerobic exercise training [128, 129]R e -
sults from exercise training studies show higher levels of
HDL-C after exercise in most older Whites [130, 131]. Such
highly variable responses to a standardized exercise training
intervention may implicate genetic factors as contributors.
Across all adult age groups, habitual levels of physical ac-
tivityaresigniﬁcantlylowerinAAsthaninCaucasianAmeri-
cans for both men and women [132, 133]. A sedentary life-
style among older AAs leads to obesity and higher triglyc-
erides (TG) and LDL-C, but lower HDL-C [134, 135]. Con-
versely, exercise training can reduce TG and LDL-C and in-
crease HDL-C. Following 10 weeks of aerobic exercise train-
ing, Doshi et al. reported an 8% reduction in cholesterol/
HDL-C ratio in older AAs, independent of changes in body
composition [136]. Conversely, a study in South African
Blacks found no signiﬁcant change in HDL-C levels after
exercise training [137]. These studies suggest that exercise
training may increase HDL-C levels in some AAs. Signiﬁcant
interactions with APOE genotype are one possible mech-
anism by which this can occur. Interestingly, our own stand-
ardized aerobic exercise training data showed ﬁtness-related
increases in the levels of HDL-C particle size and concen-
tration in ε2/3 and ε4 AAs, though to a lower extent in ε4
carriers. Therefore, APOE and other genetic markers may
account for some of the disagreements among studies.
In our currently ongoing pilot study, we will collect pro-
spective data on APOE, HDL-C (particle size and concentra-
tion), other biomarkers, neurocognitive function, and neu-
roimaging. Data on the interactive eﬀects of HDL-C, APOE,
and aerobic exercise training on neurocognitive function,
will be used to inform the power calculation for a full-scale
clinical trial to determine the mechanism by which aerobic-
ﬁtness aﬀects neurocognitive function.
12.5. Summary of Current Knowledge, Gaps. The evidence
highlights the central role of CVD risk and chronic cerebral
oxygen deprivation to neurocognitive health. Importantly,
disorders of brain lipid metabolism are associated with
all principal pathological features of AD such as synaptic10 International Journal of Alzheimer’s Disease
transmission [44], inﬂammation, amyloid [45], and tau
pathology [44]. HDL-C is the predominant lipoprotein in
human brain circulation, and its low levels can impair mem-
ory [53–55]. Unlike total cholesterol, its brain levels reﬂect
blood level. Low levels of HDL-C is associated with hip-
pocampal atrophy in aged humans [56] and therefore likely
to be involved in the eﬀects of lipids on cognitive function.
Because HDL-C can also increase the cellular degradation of
Aβ,anddecreaseAβ-inducedneurotoxicityinneuralculture,
itislikelythatHDL-Calsoplaysanimportantroleinthebio-
chemicalproperties ofAβ amyloidformation,andAD.Aero-
bic exercise can increase HDL-C, reduce inﬂammation, im-
prove glucose homeostasis, and enhance cerebral perfusion.
Cross-sectional and few prospective studies in predomi-
nantly normal Whites samples suggested that aerobic ﬁtness
can enhance cognitive function [96, 102, 116, 125, 138].
The outcome of these studies are hardly deﬁnitive, and the
mechanismbywhichﬁtnessadaptationaﬀectcognitivefunc-
tion remains to be fully elucidated. Though we and others
have shown that exercise can increase HDL-C (Figure 3),
the eﬀect of aerobic ﬁtness-induced changes in HDL-C on
preservation of neurocognitive function is yet to be examin-
ed. Further, whether these changes correlate with changes in
cerebral glucose homeostasis is not known. Future studies
must focus not just on CVD risk factors and brain infarcts,
butalsoonitssurrogatessuchasincreasedvascularresistance
and chronic cerebral oxygen insuﬃciency with or without
infarcts as well as decreased oxygenation associated with age-
related decline in pulmonary function. The role of HIF in
these cascades of events must also be considered.
Consistently,theAPOEgenehasbeenshowntoinﬂuence
bothHDL-CmetabolismandindependentlyADrisk.Inview
of the susceptibility of HDL-C to aerobic ﬁtness and the
importance of APOE gene to HDL metabolism, it is vital to
examine the eﬀects of APOE on AD risk and its relation-
ship to aerobic ﬁtness-induced increases in HDL-C. Given
potential multiple ways in which exercise may improve cog-
nitive performance and therefore reduce AD risk and the
relatively large aerobic ﬁtness-related eﬀect size reported in
manystudies,clinicaltrialsareneededtodeterminetheeﬀect
of aerobic exercise-training on cognitive function in patients
with mild AD, notwithstanding the recent NIA consensus
statement on general lack of progress.
The demonstration of training-related improvements in
neurocognitive function and regional cerebral glucose utili-
zation independent of or interactively with APOE gene
would provide momentum for a large-scale clinical trial.
A concomitant improvements in HDL-C and inﬂammatory
markers will signiﬁcantly advance knowledge of the mech-
anism by which aerobic ﬁtness aﬀects neurocognitive func-
tion. A study with the advantage of an experimental design,
the use of a control group, and ability to examine the con-
tribution of putative CVD risk factors to AD development
and progression is highly desirable. In addition to inform-
ing the mechanism by which aerobic ﬁtness can enhance
neurocognitive vitality in humans in a subsequent large-
scale clinical trial, it will help quantify the eﬀects of aero-
bic ﬁtness on biomarkers, neurodegeneration, and brain
glucose homeostasis. For populations such as AAs with
disproportionately higher rates of CVD risk and pathology, a
conﬁrmatory large scale trial will validate the role of aerobic
ﬁtness as an adjunct treatment to ameliorate the physical,
psychological, and economic burden associated with AD at
individuallevels.Inadditiontoprovidingevidenceleadingto
a scientiﬁc basis for a change in health policy and standard of
care, society is also likely beneﬁt from reduction in the econ-
omic burden.
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